Method of monitoring compliance with methadone treatment program

• US 6,124,136 A
• Filed: 11/02/1993
• Issued: 09/26/2000
• Est. Priority Date: 11/02/1993
• Status: Expired due to Term

• Current Assignee: UD Testing Incorporated (U.D. Testing)
• Original Assignee: UD Testing Incorporated (U.D. Testing)
• Inventors: Kell, Michael
• Primary Examiner(s): ALEXANDER, LYLE
• Application Number:
  US08/145,821
• Time in Patent Office: 2,520 Days
• Field of Search: 436/111, 436/816, 436/901, 422/61
• US Class Current: 436/111
• CPC Class Codes: G01N 33/493 urine
• CPC Class Codes: G01N 33/9486 Analgesics, e.g. opiates, aspirine
• CPC Class Codes: Y10S 436/816 Alkaloids, amphetamines, and barbiturates
• CPC Class Codes: Y10S 436/901 Drugs of abuse, e.g. narcotics, amphetamine
• CPC Class Codes: Y10T 436/173845 Amine and quaternary ammonium

Abstract

A method of monitoring compliance of a patient that has been placed on a methadone maintenance program by determining plasma methadone concentration from urine methadone concentration. An unadulterated urine sample is obtained from the patient. The urine methadone concentration, pH, and specific gravity are measured. The plasma methadone concentration is calculated as a function of urine methadone concentration, specific gravity, and pH. The calculated plasma methadone concentration is compared with an expected value for the maintenance program prescribed.

Claims

1. A method of monitoring compliance of a patients that has been placed on a methadone maintenance program which comprises the steps of

(a) obtaining a sample of the patient'"'"'s urine,

(b) measuring the concentration of methadone, the specific gravity and the pH value of the urine sample,

(c) calculating the concentration of methadone of the plasma as a function of the measured concentration of methadone of the urine, urine specific gravity, and urine pH, and

(d) comparing the calculated concentration of methadone of the plasma with an expected value for the maintenance program prescribed.

2. The method of claim 1 wherein the urine sample is also tested for adulteration.

3. The method of claim 2 wherein testing for adulteration comprises measuring the creatinine level of the urine sample and comparing the measured creatinine level with a predetermined normal level of creatinine of the patient.

4. The method of claim 1 wherein step (b) the concentration of methadone is measured by fluorescence polarization immunoassay.

5. The method of claim 1 wherein step (c) the concentration of methadone of the plasma is calculated in accordance with the equation

6. A method of monitoring compliance of a patient that has been placed on a methadone maintenance program with a prescribed methadone dose which comprises the steps of

(a) obtaining a sample of the patient'"'"'s urine,

(b) measuring the concentration of methadone, the specific gravity and the pH value of the urine sample,

(c) calculating a normalized urine methadone concentration as a function of the measured urine methadone concentration, prescribed methadone dose, urine specific gravity, and urine pH, and

(d) comparing the present normalized urine methadone concentration with a previously determined historical base values for the patient'"'"'s normalized urine methadone concentration to verify compliance;

whereby if the patient is in compliance with his/her prescribed dose, the present and historical base values of the patient'"'"'s normalized urine methadone concentration are similar.

7. The method of claim 6 wherein the urine sample is tested for adulteration.

8. The method of claim 7 wherein testing for adulteration comprises measuring the creatinine level of the urine sample and comparing the measured creatinine level with a predetermined normal level of creatinine of the patient.

9. The method of claim 6 wherein step (b) the concentration of methadone is measured by fluorescence polarization immunoassay.

10. The method of claim 6 wherein step (c) the normalized urine methadone concentration is calculated in accordance with the equation:

space="preserve" listing-type="equation">nu={(k.sub.1 /DOSE).sup.k2 }·

{(k.sub.3 /pH).sup.-k4 }·

(WGT/k.sub.5)·

(k.sub.6 ·

SGF -k.sub.7)·

u

where nu is the calculated normalized urine methadone concentration, DOSE is the prescribed methadone dose, pH is the pH of the spot urine sample, SGF is the specific gravity factor of the patient'"'"'s urine, u is the measured urine methadone concentration of the spot urine sample, WGT is the current patient'"'"'s body weight, and k₁ -k₇ are constants.

16. The method of claim 6 further comprising the step of measuring the patient'"'"'s body weight, and wherein calculating the normalized urine methadone concentration also as a function of the measured patient'"'"'s body weight.

11. A method of determining plasma methadone concentration from urine which comprises the steps of

(a) obtaining a sample of the patient'"'"'s urine,

(b) measuring the concentration of methadone, the specific gravity and the pH value of the urine sample, and

(c) calculating the concentration of methadone of the plasma as a function of the measured concentration of methadone of the urine, urine specific gravity, and urine pH.

12. The method of claim 11 wherein the urine sample is also tested for adulteration.

13. The method of claim 12 wherein testing for adulteration comprises measuring the creatinine level of the urine sample and comparing the measured creatinine level with a predetermined normal level of creatinine of the patient.

14. The method of claim 11 wherein step (b) the concentration of methadone is measured by fluorescence polarization immunoassay.

15. The method of claim 11 wherein step (c) the concentration of methadone of the plasma is calculated in accordance with the equation